
What is claimed is:

1. A compound having the general formula **I**



I

or a salt thereof, wherein:

R^1 is H or (1-6C alkyl);

R^2 is H, (1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)difluoroalkyl, -(1-6C)trifluoroalkyl, -(1-6C)chloroalkyl, -(2-6C)chlorofluoroalkyl, -(2-6C)difluorochloroalkyl, -(2-6C)chlorohydroxyalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO_2NH_2, -(1-6C alkyl)$NHSO_2$(1-3C alkyl), -(1-6C alkyl)NH_2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)$_2$, -(1-6C alkyl)NHC(=O)O(1-4C alkyl), -(1-6C alkyl)hetCyc^1, -(1-6C alkyl)hetAr^1, hetAr^2, hetCyc^2, -O(1-6C alkyl) which is optionally substituted with halogen, OH or (1-4C)alkoxy, -O(3-6C cycloalkyl), Cyc^1, -(1-6C alkyl)(3-6C cycloalkyl), -(1-6Calkyl)(1-4C alkoxy), -(1-6C hydroxyalkyl)(1-4C alkoxy), a bridged 7-membered cycloalkyl ring optionally substituted with (1-6C)hydroxyalkyl, or a bridged 7-8 membered heterocyclic ring having 1-2 ring nitrogen atoms;

or NR^1R^2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from (1-6C)alkyl, OH, CO_2H, (1-3C alkyl)CO_2H, -O(1-6C alkyl) and (1-6C)hydroxyalkyl;

hetCyc^1 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc^1 is optionally substituted with oxo, OH, halogen or (1-6C)alkyl;

hetCyc^2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc^2 is optionally substituted with F, SO_2NH_2, SO_2(1-3C alkyl) or halogen;

hetAr^1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-4C)alkyl;

hetAr^2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-4C)alkyl, (3-6C)cycloalkyl, halogen and OH;

Cyc^1 is a 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, $-CO_2H$, -(1-4C alkyl)OH, halogen and CF_3;

Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkoxy, $-CF_3$ $-CHF_2$, -O(1-4C alkyl)$hetCyc^3$, -(1-4C alkyl)$hetCyc^3$, –O(1-4C alkyl)O(1-3C alkyl) and -O(3-6C dihydroxyalkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, –O(1-4C alkyl), (1-4C)alkyl and NH_2, or (iii) a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected from halogen and (1-4C)alkyl;

$hetCyc^3$ is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-6C)alkyl;

X is $-CH_2-$, $–CH_2CH_2-$, $-CH_2O-$ or $-CH_2NR^d-$;

R^d is H or -(1-4C alkyl);

R^3 is H or -(1-4C alkyl);

each R^4 is independently selected from halogen, -(1-4C)alkyl, -OH, -(1-4C)alkoxy, $-NH_2$, -NH(1-4C alkyl) and $-CH_2OH$; and

n is 0, 1, 2, 3, 4, 5 or 6.

2. A compound of claim 1, wherein:

R^1 is H or -(1-6C alkyl);

R^2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO_2NH_2, -(1-6C alkyl)$NHSO_2$(1-3C alkyl), -(1-6C alkyl)NH_2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)$_2$, -(1-6C alkyl)$hetCyc^1$, -(1-6C alkyl)$hetAr^1$, $hetAr^2$, $hetCyc^2$, -O(1-6C alkyl), -O(3-6C cycloalkyl), Cyc^1, or a bridged 7-membered cycloalkyl ring,

or NR^1R^2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, -OH, $-CO_2H$ and -(1-3C alkyl)CO_2H;

$hetCyc^1$ is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein $hetCyc^1$ is optionally substituted with oxo;

hetCyc^2 is a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc^2 is optionally substituted with F, SO_2NH_2, or SO_2(1-3C alkyl);

hetAr^1 is a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with -(1-4C)alkyl;

hetAr^2 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from -(1-4C)alkyl;

Cyc^1 is 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, $-CO_2H$ and -(1-4C alkyl)OH;

Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, $-CF_3$ $-CHF_2$, -O(1-4C alkyl)hetCyc^3 and –O(1-4C alkyl)O(1-3C alkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, –O(1-4C alkyl) and (1-4C)alkyl;

hetCyc^3 is a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;

X is $-CH_2-$, $-CH_2CH_2-$, $-CH_2O-$ or $-CH_2NR^d-$;

R^d is H or -(1-4C alkyl);

R^3 is H or -(1-4C alkyl);

each R^4 is independently selected from halogen, -(1-4C)alkyl, -OH, -(1-4C)alkoxy, NH_2, NH(1-4C alkyl) and CH_2OH; and

n is 0, 1, 2, 3, 4, 5 or 6.

3. A compound according to claims 1 or 2, wherein:

R^1 is H or -(1-6C alkyl); and

R^2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO_2NH_2, -(1-6C alkyl)$NHSO_2$(1-3C alkyl), -(1-6C alkyl)NH_2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)$_2$, -(1-6C alkyl)hetCyc^1, -(1-6C alkyl)hetAr^1, hetAr^2, -O(1-6C alkyl), -O(3-6C cycloalkyl), or a 3, 4 or 5 membered cycloalkyl ring optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, $-CO_2H$ and -(1-4C alkyl)OH,

or NR^1R^2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, -OH, $-CO_2H$ and -(1-3C alkyl)CO_2H.

4. A compound according to claims 1 or 2, wherein:

R^1 is H or -(1-6C alkyl);

R^2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO_2NH_2, -(1-6C alkyl)$NHSO_2$(1-3C alkyl), -(1-6C alkyl)NH_2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)$_2$, -(1-6C alkyl)hetCyc^1, -(1-6C alkyl)hetAr^1, hetAr^2, hetCyc^2, -O(1-6C alkyl), -O(3-6C cycloalkyl), or a bridged 7-membered cycloalkyl ring,

or NR^1R^2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, -OH, $-CO_2H$ and -(1-3C alkyl)CO_2H.

5. A compound according to any of claims 1-4, wherein R^2 is H or -(1-6C)alkyl.

6. A compound of claim 5, wherein R^2 is -(1-6C)alkyl.

7. A compound of claim 6, wherein R^2 is methyl, ethyl, isopropyl or tert-butyl.

8. A compound of claim 5, wherein R^2 is H.

9. A compound according to any of claims 1-4, wherein R^2 is -(1-6C)hydroxyalkyl or -(2-6C)dihydroxyalkyl.

10. A compound of claim 9, wherein R^2 is CH_2CH_2OH, $CH_2CH(OH)CH_2OH$ or $C(CH_3)(CH_2OH)_2$.

11. A compound of claim 1 or 2, wherein R^2 is Cyc^1 or a bridged 7-membered cycloalkyl ring.

12. A compound according to claim 11, wherein R^2 is Cyc^1 optionally substituted with optionally substituted with one or two substituents independently selected from methyl, -OH, $-CH_2OH$ and $-CO_2H$.

13. A compound according to claim 12, wherein R^2 is cyclopropyl.

14. A compound of claim 1 or 2, wherein Cyc^1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, $-CO_2H$ and -(1-4C alkyl)OH.

15. A compound of claim 1, wherein Cyc^1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, $-CO_2H$, -(1-4C alkyl)OH, halogen and CF_3.

16. A compound according to claim 1 or 2, wherein R^2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, $-CO_2H$ and -(1-4C alkyl)OH.

17. A compound according to claim 16, wherein R^2 is cyclopropyl optionally substituted with one or more substituents independently selected from methyl, $-CO_2H$, or $-CH_2OH$.

18. A compound of claim 1 or 2, wherein R^2 is -O(1-6C alkyl) or -O(3-6C cycloalkyl).

19. A compound of claim 18, wherein R^2 is selected from -OMe, -OEt and cyclopropoxy.

20. A compound of claim 1 or 2, wherein R^2 is selected from -(1-6C)fluoroalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO_2NH_2, and -(1-6C alkyl)$NHSO_2$(1-3C alkyl).

21. A compound of claim 20, wherein R^2 is selected from $-C(CH_3)_2CH_2F$, $-C(CH_3)_2CH_2OH$, $CH_2C(CH_3)_2OH$, $-CH_2CN$, $-C(CH_3)_2CN$, $-CH_2CH_2SO_2NH_2$, $-CH_2CH_2NHSO_2CH_3$ and $-C(CH_3)_2CH_2NHSO_2CH_3$.

22. A compound of claim 1 or 2, wherein R^2 is selected from -(1-6C alkyl)NH_2, -(1-6C alkyl)NH(1-4C alkyl) and -(1-6C alkyl)N(1-4C alkyl)$_2$.

23. A compound of claim 22, wherein R^2 is selected from $-CH_2C(CH_3)_2NH_2$, $-C(CH_3)_2NHCH_3$ and –(1-6C alkyl)NMe_2.

24. A compound of claim 1 or 2, wherein R^2 is selected from -(1-6C alkyl)hetCyc^1 and -(1-6C alkyl)hetAr^1.

25. A compound of claim 1 or 2, wherein R^2 is selected from -(1-6C alkyl)hetAr^1 and hetAr^2.

26. A compound according to any of claims 1-25, wherein R^1 is H.

27 A compound of claim 1, wherein NR^1R^2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, -OH, $-CO_2H$ and -(1-3C alkyl)CO_2H.

28. A compound according to any of claims 1-27, wherein X is $-CH_2-$ or $-CH_2CH_2-$.

29. A compound of claim 28 wherein X is $-CH_2-$.

30. A compound according to any of claims 1-27, wherein X is $-CH_2O-$.

31. A compound according to any of claims 1-27, wherein X is $-CH_2NR^d-$.

32. A compound according to any of claims 1-31, wherein Y is phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, CF_3, CHF_2, -O(1-4C alkyl)hetCyc^3, -(1-4C alkyl)hetCyc^3 and –O(1-4C alkyl)O(1-3C alkyl).

33. A compound of claim 32, wherein Y is phenyl optionally substituted with one or more substituents independently selected from -F, -Cl, -OMe, $-CF_3$, $-CHF_2$, morpholinylethoxy, morpholinylethyl and $-OCH_2CH_2OMe$.

34. A compound of claim 33, wherein Y is phenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 2-methoxyphenyl, 2-methoxy-5-fluorophenyl, 2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-(2-morpholinylethoxy)phenyl, 3-fluoro-5-(2-morpholinylethyl)phenyl, 5-fluoro-2-(2-morpholinylethyl)phenyl, 3-fluoro-5-methoxyethoxyphenyl or 5-fluoro-2-methoxyethoxyphenyl.

35. A compound according to any of claims 1-31, wherein Y is fluorophenyl optionally substituted with a substituent selected from -O(1-4C alkyl)hetCyc^3, –O(1-4C alkyl)O(1-3C alkyl) and -O(3-6C dihydroxyalkyl).

36. A compound of claim 35, wherein Y is fluorophenyl substituted with a substituent selected from morpholinylethoxy, $-OCH_2CH_2OMe$, 2,3-dihydroxypropoxy and 2,2-dimethyl-1,3-dioxolanyl.

37. A compound of claim 34, wherein Y is 2,5-difluorophenyl.

38. A compound according to any of claims 1-31, wherein Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said ring is optionally substituted with one or more substituents independently selected from halogen, –O(1-4C alkyl) and (1-4C)alkyl.

39. A compound of claim 38, wherein Y is pyridyl optionally substituted with one or more substituents independently selected from F, -OMe and Me.

40. A compound of claim 39, wherein Y is pyrid-2-yl, pyrid-3-yl, 5-fluoropyrid-3-yl, 2-methoxy-5-fluoropyridy-3-yl or 2-methyl-5-fluoropyridy-3-yl.

41. A compound according to any of claims 1-31, wherein Y is a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said ring is substituted with one or more substituents independently selected from halogen and (1-4C)alkyl.

42. A compound of claim 41, wherein Y is pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl.

43. A compound of claim 42, wherein Y is 5-fluoropyrid-3-yl, 2-methyl-5-fluoropyrid-3-yl or 2-ethyl-5-fluoropyrid-3-yl.

44. A compound of claim 40 or 43, wherein Y is 5-fluoropyrid-3-yl.

45. A compound according to any of claims 1-31, wherein Y is a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected form halogen and (1-4C)alkyl.

46. A compound of claim 45, wherein Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.

47. A compound of claim 1, wherein:

R^1 is H or -(1-6C alkyl);

R^2 is H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SO_2NH_2, -(1-6C alkyl)$NHSO_2$(1-3C alkyl), -(1-6C alkyl)NH_2, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl)$_2$, -(1-6C alkyl)hetCyc^1, -(1-6C alkyl)hetAr^1, hetAr^2, hetCyc^2, -O(1-6C alkyl), -O(3-6C cycloalkyl), or Cyc^1;

or NR^1R^2 forms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, -OH, -CO_2H and -(1-3C alkyl)CO_2H;

Cyc^1 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), -OH, -OMe, -CO_2H and -(1-4C alkyl)OH.

X is CH_2; and

Y is (i) fluorophenyl optionally substituted with a substituent selected from -O(1-4C alkyl)hetCyc^3, -(1-4C alkyl)hetCyc^3, –O(1-4C alkyl)O(1-3C alkyl) and -O(3-6C dihydroxyalkyl), (ii) pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl, or (iii) 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.

48. A compound of claim 47, wherein Y is fluorophenyl optionally substituted with a substituent selected from -O(1-4C alkyl)hetCyc^3, -(1-4C alkyl)hetCyc^3, –O(1-4C alkyl)O(1-3C alkyl) and -O(3-6C dihydroxyalkyl).

49. A compound of claim 47, wherein Y is pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl.

50. A compound of claim 47, wherein Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.


51. A compound according to any of claims 47-50, wherein R^2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C)alkyl, -OH, -OMe, -CH_2OH and -(1-4C)alkylOH.

52. A compound according to claim 51, wherein R^4 is OH, F, methyl, or CH_2OH.

53. A compound according to claim 52, wherein n is 0, 1 or 2.

54. A compound according to claim 53, wherein R^3 is hydrogen.

55. A compound according to any of claims 1-54, wherein Y has the absolute configuration of Figure Ia:



Ia

56. A compound according to any of claims 1-55, wherein R^3 is H.

57. A compound according to any of claims 1-56, wherein n is 0-2 and R^4 is F or Me.

58. A compound according to claim 57, wherein n is 0.

59. A pharmaceutical composition, which comprises a compound of Formula I as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.


60. A compound of Formula I as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection in a mammal.

61. The compound of claim 60, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is pain.

62. The use of a compound of Formula I as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.

63. A process for the preparation of a compound of claim 1, which comprises:


(a) reacting a corresponding compound of Formula **II**



II

with an amine having the formula HNR^1R^2; or


(b) for compounds of Formula **I** where R^1 and R^2 are each hydrogen, reacting a compound of Formula **III**



III

with an inorganic acid; or


(c) for a compound of Formula **I** where R^2 is (alkyl)$NHSO_2$((1-3C alkyl), reacting a compound having the formula **IV**



IV

with (1-3C alkyl)SO_2Cl; or


(d) for compounds of Formula I wherein Y is 5-fluoropyridin-2(1H)-one, treating a corresponding compound having the formula **VIII**



VIII

with an acid at elevated temperatures; or


(e) for a compound of Formula **I** wherein R^2 is $CH_2CH(OH)CH_2OH$, treating a corresponding compound having the formula **IX**



IX

with an acid; or

(f) for a compound of Formula **I** wherein Y is fluorophenyl substituted with -$OCH_2CH(OH)CH_2OH$, treating a corresponding compound having the formula **X**



X

with an acid; and

removing or adding any protecting groups if desired, and forming a salt if desired.

CLAIMS

1. An invention not claimed in any divisional application.